Clinical Trials Browser

Colonic Neoplasms × durvalumab × Clear all

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT04068610 2026-03-02

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Phase 1/2 Active not recruiting

61 enrolled 35 charts

Gastrointestinal

Colonic Neoplasms

NCT04108481 2025-03-28

iRE-C

Phase 1 Terminated

5 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03428126 2023-06-15

Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer

Phase 2 Completed

29 enrolled 9 charts

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT04145193 2020-09-21

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

Clinical Trials

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

iRE-C

Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC